Published in Health and Fitness on Tuesday, August 28th 2012 at 5:35 GMT by Market Wire
^{🞛 This publication is a summary or evaluation of another publication}

WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics -- SHANGHAI and TAIPEI, Aug. 28, 2012 /PRNewswire-Asia/ --

WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics

[ ]

SHANGHAI and TAIPEI, Aug. 28, 2012 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: [ WX ]) today announced that it has a contract manufacturing agreement with TaiMed Biologics Inc. for the manufacture of ibalizumab (TMB-355) in support of Phase 2 and Phase 3 clinical trials globally. Ibalizumab is a humanized monoclonal antibody and a member of an emerging class of HIV therapies known as viral-entry inhibitors. This work will be completed at WuXi's biologics manufacturing facilities in China and its biologics testing facilities in the United States.

"We are pleased that TaiMed Biologics has selected WuXi to manufacture ibalizumab for its global clinical trials because of WuXi's strong technical capabilities and high quality standards," said Edward Hu, Chief Operating Officer of WuXi PharmaTech. "WuXi's integrated biological drug discovery, development, manufacturing and testing service platform provides our customers with a seamless solution to bring their biologics products to the market globally and in China."

"TaiMed looks forward to working with WuXi to produce clinical-trial supplies of this important new medicine for patients," said James Chang, Chief Executive Officer of TaiMed Biologics. "We are delighted to have such a skilled and reputable partner in WuXi for late-stage manufacturing as we further develop the subcutaneous formulation of our lead product, ibalizumab."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit [ http://www.wuxiapptec.com ].

About TaiMed Biologics

TaiMed Biologics, Inc. is a publicly held Taiwanese biotechnology company with the mission to discover, develop and deliver for the global market innovative medicines that help patients prevail over serious infectious diseases. For more information, please visit [ http://www.taimedbiologics.com ].

WuXi PharmaTech

Aaron Shi (for the media)
Tel: +86-21-5046
Email: [ Aaron_Shi@wuxiapptec.com ]

Ronald Aldridge (for investors)
Tel: +1-201-585-2048
Email: [ Ron_Aldridge@wuxiapptec.com ]

TaiMed Biologics

James N. Chang, PhD
Chief Executive Officer, TaiMed Biologics

Tel: 1-949-769-6543 (USA), 886-2-2655-8031 (Taiwan)
Email: [ jchang@taimedbiologics.com ]

SOURCE WuXi PharmaTech (Cayman) Inc.

[ Back to top ]

Publication Contributing Sources

Market Wire

N🟁N

WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics

WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics